Transfusions of “Old” Blood May Harm Some Patients

Maximum shelf life of red blood cells should be reduced, Columbia University researchers recommend

NEW YORK, NY (Jan. 9, 2017)—The oldest blood available for transfusions releases large and potentially harmful amounts of iron into patients’ bloodstreams, a new study by researchers at Columbia University Irving Medical Center (CUIMC) has found.

Based on the new findings, the researchers recommend that the FDA reduce the maximum storage limit of red blood cells from six weeks to five weeks, as long as sufficient blood supplies are available.

“Our recommendation will be controversial, but we think we have real data to support it,” said the study’s co-leader Steven Spitalnik, MD, professor of pathology & cell biology at Columbia and medical director of the clinical laboratories at NewYork-Presbyterian/Columbia. “Recent studies have concluded that transfusing old blood has no impact on patient outcomes, but those studies didn’t exclusively examine the oldest blood available for transfusions. Our new study found a real problem when transfusing blood that’s older than five weeks.”

Their findings appear in the January issue of the Journal of Clinical Investigation.

Transfusion of red blood cells is the most common procedure performed in hospitalized patients, with approximately 5 million patients receiving red blood cell transfusions annually in the United States. “But the longer you store blood, the more the cells become damaged,” said the study’s co-leader Eldad Hod, MD, associate professor of pathology & cell biology at Columbia and clinical pathologist at NewYork-Presbyterian/Columbia. Currently, the U.S. FDA allows units of red blood cells to be stored for up to six weeks before they must be discarded.

In the study, the researchers randomly assigned a group of 60 healthy volunteers to receive a unit of red blood cells that had been stored for one, two, three, four, five, or six weeks. The volunteers were then monitored for 20 hours after transfusion.

Within hours after transfusion, seven of the nine volunteers who received the 6-week-old blood could not appropriately metabolize the damaged cells, thereby releasing large amounts of iron into their bloodstream. Only one volunteer who received younger blood had a similar response, with blood that had been stored for five weeks.

None of the volunteers were harmed by the transfusion, but previous studies have shown that excess iron can enhance blood clots and promote infections. “Based on the amount of iron circulating in the blood of the volunteers who received 6-week-old blood, we’d predict that certain existing infections could be exacerbated,” said Dr. Hod.

“Thus, for ill, hospitalized patients, this excess iron could lead to serious complications,” said Dr. Spitalnik.

The true impact of 6-week-old blood on the rate of complications in patients is likely to be small, the researchers said, but since millions of Americans receive transfusions each year, even a 1 percent difference in complications could affect a large number of patients.

“It’s estimated that up to 10 to 20 percent of blood units used for transfusions have been stored for more than five weeks, so the number of patients who are likely to receive a unit of very old blood is substantial,” Dr. Hod added.

“Based on our findings of potential harm, we think the prudent thing to do at this time is for the FDA to reduce the maximum storage period,” said Dr. Spitalnik. “The U.K., Ireland, the Netherlands, and the National Institutes of Health have limited storage to 35 days, and we think that can be achieved throughout the U.S. without seriously affecting the blood supply.”

About the study:

The study is titled “Prolonged red cell storage before transfusion increases extravascular hemolysis.” The other authors are Francesca Rapido (Universita degli Studi di Milano); Gary Brittenham, Sheila Bandyopadhyay, Francesca La Carpia, Camilla L’Acqua, Donald J. McMahon, Abdelhadi Rebbaa, Boguslaw S. Wojczyk, Jane Netterwald, Hangli Wang, Joseph Schwartz, Andrew Eisenberger, Mark Soffing, Randy Yeh, and Chaitanya Divgi (CUIMC); Yelena Z. Ginzburg and Beth H. Shaz (New York Blood Center); and Richard O. Francis (CUIMC).

The study was supported by grants from the National Institutes of Health (HL115557 and UL1TR000040).

The authors have declared no conflicts of interests.

###

Columbia University Irving Medical Center provides international leadership in basic, preclinical, and clinical research; medical and health sciences education; and patient care. The medical center trains future leaders and includes the dedicated work of many physicians, scientists, public health professionals, dentists, and nurses at the College of Physicians and Surgeons, the Mailman School of Public Health, the College of Dental Medicine, the School of Nursing, the biomedical departments of the Graduate School of Arts and Sciences, and allied research centers and institutions. Columbia University Irving Medical Center is home to the largest medical research enterprise in New York City and State and one of the largest faculty medical practices in the Northeast. Columbia University Irving Medical Center shares a campus with its hospital partner, NewYork-Presbyterian. For more information, visit cuimc.columbia.edu or columbiadoctors.org.